MedPath

An Intervention Program to Reduce to the Risk of Persistent Symptoms After Concussion

Phase 2
Completed
Conditions
Mild Traumatic Brain Injury
Interventions
Behavioral: Treatment as usual
Behavioral: Cognitive-behavioural therapy
Registration Number
NCT00893347
Lead Sponsor
University of British Columbia
Brief Summary

This study investigates how well a new therapy program prevents persistent symptoms (e.g., headaches, fatigue, irritability, etc.) after concussion. The program involves examining beliefs about concussion and learning healthy coping strategies, and is completed with the first three months post-injury.

Detailed Description

Although the majority of patients with mild traumatic brain injury (MTBI) experience complete recovery within three months, a sizeable group continues to report frequent and severe symptoms such as headaches, fatigue, difficulty concentrating, forgetfulness, and irritability, in what is labeled persistent post-concussion syndrome (PCS). Persistent PCS is associated with vocational, recreational, and social disability. Early education and reassurance (treatment as usual) is effective in general, but appears insufficient for this subgroup.

Recent research has identified risk factors for persistent PCS, including inaccurate illness beliefs, maladaptive coping behaviour, and emotional distress. The present study will evaluate the additive efficacy of a cognitive-behavioural therapy protocol designed to modify these risk factors, over and above treatment as usual.

Participants with MTBI will be recruited within six weeks of injury. Those identified as being at-risk for persistent PCS based on evidence-based criteria will receive treatment as usual and then be randomly assigned to receive either no further intervention or cognitive-behavioural therapy. We hypothesize that the group receiving cognitive-behavioural therapy will have fewer PCS symptoms and be less disabled at follow-up. We also hypothesize that compensation-seeking status will mitigate this improvement and that illness beliefs, coping behaviour, and emotional distress will mediate this improvement. A blinded rater will conduct the baseline and outcome assessments.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
28
Inclusion Criteria
  • Incurred head trauma within six weeks of study entry
  • Meet American Congress of Rehabilitation criteria for MTBI, documented by the referring/treating physician
  • Subjective report at least one symptom attributable to head trauma
  • English as preferred language for communication
  • Considered at-risk for persistent PCS based on prognostic model from Whittaker et al. (2007)
Exclusion Criteria
  • Medical documentation of skull fracture or acute intracranial abnormality on neuroimaging, consistent with "mild-complicated" TBI
  • Self-reported history of a neurological disorder (including prior MTBI within the past six months)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ITreatment as usualTreatment as usual
IITreatment as usualTreatment as usual + cognitive-behavioural therapy
IICognitive-behavioural therapyTreatment as usual + cognitive-behavioural therapy
Primary Outcome Measures
NameTimeMethod
PCS symptoms (Rivermead Postconcussion Symptoms Questionnaire)Pre-intervention and three months later
Functional disability (Mayo-Portland Participation Index)Pre-intervention and three months later
Secondary Outcome Measures
NameTimeMethod
Illness beliefs (Illness Perceptions Questionnaire-Revised)Pre-intervention and three months later
Coping style (PCS Coping Inventory)Pre-intervention and three months later
Psychological distress (Hospital Anxiety and Depression Scale) )Pre-intervention and three months later
Pain (Brief Pain Scale)Pre-intervention and three months later
Psychiatric diagnosis (MINI International Neuropsychiatric Interview)Pre-intervention and three months later

Trial Locations

Locations (1)

GF Strong Rehab Centre, 4255 Laurel Street

🇨🇦

Vancouver, British Columbia, Canada

© Copyright 2025. All Rights Reserved by MedPath